Garadacimab (also known as CSL312) is an experimental medication designed for preventing attacks in people with hereditary angioedema (HAE). It works by targeting a specific protein in the body that is involved in swelling episodes. The medication is given as an injection under the skin (subcutaneous injection) and is being studied as a preventive treatment to reduce the frequency of HAE attacks.

C1-INH (C1 esterase inhibitor) is a protein that helps regulate various body processes including swelling. In people with hereditary angioedema, there is either not enough C1-INH or it doesn’t work properly. This trial is studying how garadacimab works in patients with this specific type of HAE related to C1-INH deficiency.

Hereditary Angioedema – A rare genetic condition characterized by recurrent episodes of severe swelling in various parts of the body. The swelling typically affects the hands, feet, face, digestive tract, and airways. Episodes can occur spontaneously or be triggered by stress, minor trauma, or other factors. The condition is caused by a deficiency or dysfunction of a blood protein called C1 inhibitor, which helps regulate various body processes. The swelling develops slowly over several hours and usually subsides within 2-5 days. Between episodes, patients may have no visible symptoms.